A study in 52 patients with NSCLC also found that patients with TP53 mutations had a higher risk of progression regardless of PD-L1 expression (HR = 3.3), although the result was not significant (p = 0.05)59. This evidence concerns the gene TP53 and non-small cell lung carcinoma.